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Abstract 
Background 
Semaphorins (SEMAs) consist of a large family of secreted and membrane-anchored 
proteins that are important in neuronal pathfinding and axon guidance in selected areas 
of the developing nervous system. Of them, SEMA7A has been reported to have a 
chemotactic activity in neurogenesis and to be an immunomodulator; however, little is 
known about the relevance of SEMA7A in the behaviors of oral squamous cell 
carcinoma (OSCC).  
Methods 
We evaluated SEMA7A expression in OSCC-derived cell lines and primary OSCC 
samples using quantitative reverse transcriptase-polymerase chain reaction, 
immunoblotting, and semiquantitative immunohistochemistry (sq-IHC). In addition, 
SEMA7A knockdown cells (shSEMA7A cells) were used for functional experiments, 
including cellular proliferation, invasiveness, and migration assays. We also analyzed 
the clinical correlation between SEMA7A status and clinical behaviors in patients with 
OSCC.  
Results 
SEMA7A mRNA and protein were up-regulated significantly (P<0.05) in OSCC-
derived cell lines compared with human normal oral keratinocytes. The shSEMA7A 
cells showed decreased cellular growth by cell-cycle arrest at the G1 phase, resulting 
from up-regulation of cyclin-dependent kinase inhibitors (p21
Cip1
 and p27
Kip1
) and down-
regulation of cyclins (cyclin D1, cyclin E) and cyclin-dependent kinases (CDK2, CDK4, 
and CDK6); and decreased invasiveness and migration activities by reduced secretion of 
matrix metalloproteases (MMPs) (MMP-2, proMMP-2, pro-MMP-9), and expression of 
membrane type 1- MMP (MT1-MMP). We also found inactivation of the extracellular 
regulated kinase 1/2 and AKT pathways, an upstream molecule of cell-cycle arrest at the 
G1 phase, and reduced secretion of MMPs in shSEMA7A cells. sq-IHC showed that 
SEMA7A expression in the primary OSCCs was significantly (P=0.001) greater than 
that in normal counterparts and was correlated with primary tumoral size (P=0.0254) and 
regional lymph node metastasis (P=0.0002). 
Conclusion 
Our data provide evidence for an essential role of SEMA7A in tumoral growth and 
metastasis in OSCC and indicated that SEMA7A may play a potential 
diagnostic/therapeutic target for use in patients with OSCC. 
 
 
Introduction 
Semaphorins (SEMAs), secreted and membrane-associated proteins, provide 
environmental cues to mediate diverse developmental processes including neuronal 
cellular migration, axon guidance, vasculogenesis, branching morphogenesis, and cardiac 
organogenesis [1]. SEMA abnormalities have been implicated in the pathogenesis of 
neurologic disorders, such as Alzheimer’s disease and motor neuron degeneration. 
SEMAs also are expressed in the immune response systems, including B cells, T cells, 
natural killer cells, and macrophages, and have been implicated in regulation of 
organogenesis, angiogenesis, apoptosis, and neoplasia [2].  
SEMA1-8 are characterized by the presence of a conserved large SEMA domain (∼
500 amino acids) at the N-terminal domain and differentiated by their C-terminus [3]. 
SEMA1 and SEMA2 are found in invertebrates, SEMA3-7 are found in vertebrates, and 
SEMA8 is found in viruses [4]. SEMA4-7 exist primarily as membrane-bound forms, 
whereas SEMA3 is secreted as a soluble molecule. Diffusible SEMAs can elicit 
autocrine/paracrine signaling, while membrane-bound family members can mediate 
short-range juxtacrine signals. 
Although cancer cells typically express abnormal levels of SEMAs, the role of 
SEMA7A in cancer progression is largely unknown. SEMA7A, a novel transmembrane 
glycosylphosphatidylinisotol-anchored protein, was first identified in the immune system 
in myeloid and lymphoid lineage cells [5-7] and functions through β-integrins in multiple 
systems [8]. We present the results of a comprehensive analysis of molecular/cellular 
subtypes of SEMA7A in oral squamous cell carcinoma (OSCC) that are linked 
functionally and contribute clinically to tumoral progression and prognosis in OSCCs. 
 
Materials and Methods 
Ethical statement 
The Ethical Committee of the Graduate School of Medicine, Chiba University (approval 
number, 236) approved the study protocol, which was performed in accordance with 
the tenets of the Declaration of Helsinki. All patients provided written informed consent . 
 
OSCC-derived cell lines and tissue specimens 
Human OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, Sa3, Ca9-22, SAS, KOSC-2, 
Ho-1-u-1, and Ho-1-N-1) were obtained from the Human Science Research Resources 
Bank (Osaka, Japan) or the RIKEN BioResource Center (Ibaraki, Japan) through the 
National Bio-Resource Project of the Ministry of Education, Culture, Sports, Science 
and Technology in Japan. Short tandem repeat proﬁles conﬁrmed cellular identity. 
Primary cultured human normal oral keratinocytes (HNOKs) were obtained from healthy 
oral mucosa epithelium specimens collected from young patients at Chiba University 
Hospital. Three independent HNOKs were primary cultured and maintained in oral 
keratinocyte medium (ScienCell Research Laboratories, Carlsbad, CA, USA) comprised 
of 5 ml of oral keratinocyte growth supplement (ScienCell Research Laboratories) and 5 
ml of penicillin/streptomycin solution (ScienCell Research Laboratories) [9-12]. All 
OSCC-derived cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
(Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) 
(Sigma-Aldrich) and 50 units/ml penicillin and streptomycin (Sigma-Aldrich).  
One-hundred and fifty primary OSCC samples and patient-matched normal 
epithelium were obtained during surgeries performed at Chiba University Hospital. The 
resected tissues were fixed in 20% buffered formaldehyde solution for pathologic 
diagnosis and immunohistochemistry (IHC) staining. We performed histopathological 
diagnosis of each OSCC sample according to the World Health Organization criteria at 
the Department of Pathology of Chiba University Hospital [13]. The clinicopathological 
stages were determined based on the TNM classification of the International Union 
against Cancer [14]. 
mRNA expression analysis 
Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA), 
according to the manufacturer’s instructions. cDNA was generated by using ReverTra 
Ace qPCR RT Master Mix (Toyobo Life Science, Osaka, Japan) according to the 
manufacturers’ instructions. Real-time quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR) was performed in a 20-μl reaction volume using the 
Thunderbird SYBR qPCR Mix (Toyobo) on the LightCycler 480 apparatus (Roche 
Diagnostics, Mannheim, Germany), according to the manufacturer’s protocol. The 
general amplification conditions were performed as described previously [15-18]. 
Primers were designed using Primer 3Plus (on-line free software, 
http://primer3plus.com/), which specifies the most suitable set. The primer sequences 
used for qRT-PCR were: SEMA7A , forward, 5′-TGTGTATTCCCTCGGTGACA-3′; 
reverse, 5′-GAGTGGAACAATGGCGTCTT-3′; and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), forward, 5′-AACATCATCCCTGCCTCTACTGG-3′; reverse, 
5′-TTGAAGTCAGAGGAGACCACTG-3′; and MMP2, forward, 5′-
CCCCAAAACGGACAAAGAG-3′; reverse, 5′-CTTCAGCACAAACAGGTTGC-3′; 
and MMP9, forward, 5′-GAACCAATCTCACCGACAGG-3′; reverse, 5′-
GCCACCCGAGTGTAACCATA-3′; and membrane type 1- MMP (MT1-MMP), forward, 
5′-GCCTTGGACTGTCAGGAATG-3′; reverse, 5′-AGGGGTCACTGGAATGCTC-3′. 
The transcript amount for SEMA7A was estimated from the respective standard curves 
and normalized to the GAPDH transcript amount determined in corresponding samples.   
 
Immunoblotting analysis 
The cells were washed three times with cold phosphate buffered saline (PBS) and gently 
and briefly centrifuged. The cellular pellets were incubated at 4°C for 30 minutes in a 
lysis buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, and 10 mM Tris, pH 7.4) with a 
proteinase inhibitor cocktail (Roche Diagnostics). The total protein concentration was 
measured using a dye-binding method based on the Bradford assay with Bio-Rad Protein 
Assay Dye Reagent Concentrate (Bio-Rad Laboratories, Hercules, CA, USA). 
Protein extracts were electrophoresed on 4-12% Bis-Tris gel and transferred to 
nitrocellulose membranes (Invitrogen) and blocked for 1 hour at room temperature with 
Blocking One (Nacalai Tesque, Inc., Kyoto, Japan). The membranes were washed three 
times with 0.1% Tween-20 in Tris-buffered saline (TBS-T) and incubated with affinity-
purified mouse anti-SEMA7A monoclonal antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), rabbit anti-GAPDH polyclonal antibody (Santa Cruz Biotechnology), 
rabbit anti-cyclin D1 polyclonal antibody (Santa Cruz Biotechnology), rabbit anti-cyclin 
E1 polyclonal antibody (Santa Cruz Biotechnology), rabbit anti-p21
Cip1
 polyclonal 
antibody (Santa Cruz Biotechnology), rabbit anti-AKT polyclonal antibody (Santa Cruz 
Biotechnology), rabbit anti- phosphorylated-AKT (pAKT) polyclonal antibody (Santa 
Cruz Biotechnology), rabbit anti- membrane type-1 matrix metalloproteinase (MT1-
MMP) monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA), rabbit 
anti-extracellular signal-regulated kinase (ERK) 1/2 (Cell Signaling Technology), rabbit 
anti-phosphorylated-ERK1/2 (pERK1/2) (Cell Signaling Technology), rabbit anti-p27
Kip1
 
polyclonal antibody (Cell Signaling Technology), rabbit anti-cyclin-dependent kinase 
(CDK) 2 monoclonal antibody (Cell Signaling Technology), rabbit anti-CDK4 
monoclonal antibody (Cell Signaling Technology), and rabbit anti-CDK6 monoclonal 
antibody (Cell Signaling Technology) overnight at 4°C. The membrane was washed with 
TBS-T and incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse 
IgG as a secondary antibody (Promega, Madison, WI, USA), for 1 hour at room 
temperature. Finally, the membranes were detected using Super-Signal West Pico 
Chemiluminescent substrate (Thermo Fisher Scientific, Rockford, IL, USA), and 
immunoblotting was visualized by exposing the membranes to ChemiDoc XRS Plus 
system (Bio-Rad Laboratories). The signal intensities were quantitated using the Image 
Lab system (Bio-Rad Laboratories). Densitometric SEMA7A protein data were 
normalized to GAPDH protein levels. 
 
Transfection with shRNA plasmid 
OSCC-derived cells (SAS and KOSC-2) were transfected with SEMA7A shRNA 
(shSEMA7A) or control shRNA (shMock) vectors (Santa Cruz Biotechnology) 
with Lipofectamine 3000 and Plus Reagents (Invitrogen), according to the 
manufacturer’s instructions. After transfection, the cells were isolated by the 
culture medium containing 1 μg/ml puromycin (Invitrogen). Several weeks after 
transfection, a small colony was viable. The cell colonies were picked, 
transferred to six-well plates, and expand gradually to 10-cm dishes. To assess 
the efficiency of SEMA7A knockdown, we performed qRT-PCR and 
immunoblotting. 
 
Cellular growth 
To evaluate the effect of SEMA7A knockdown on cellular proliferation, we analyzed 
cellular growth in shSEMA7A and shMock cells. These cells were seeded in 6-cm 
dishes at a density of 1 × 10
4
 viable cells. At the indicated time points, the cells were 
trypsinized and counted in triplicate using a hemocytometer. 
 
Invasiveness assay 
To evaluate the effect of SEMA7A knockdown on invasiveness, a total of 2.5×10
5 
cells 
resuspended in the serum-free medium were seeded on Matrigel
®
-coated Transwell
®
 
inserts (8 μm pores) (Becton-Dickinson, Franklin Lakes, NJ, USA). In the lower chamber, 
2 ml of DMEM with 10% FBS was added as a chemoattractant. After the cells were 
incubated for 48 hours at 37°C, the insert was washed with PBS, and the cells on the top 
surface of the insert were removed with cotton swabs. Cells adhering to the lower surface 
of the membrane were fixed with methanol and stained with crystal violet. The number of 
cells that invaded through the pores in five random fields was counted using a light 
microscope at ×100 magnification. 
 
Migration assay 
The cells were seeded in six-well plates with 10% FBS/DMEM until a confluent monolayer 
formed. Using a micropipette tip, one wound was created in the middle of each plate. We 
incubated plates at 37°C at 5% carbon dioxide with free-serum medium. The results were 
visualized by measuring the wound area that was free of cells using the Lenaraf220b software 
(http://www.vector.co.jp/soft/dl/win95/art/se312811.html). The mean value was calculated 
from data obtained from six wells. 
 Cell-cycle analysis 
The transmutants were treated with 200 ng/ml nocodazole (Sigma-Aldrich) for 16 hours 
to synchronize cells at the G2/M transition [19-21]. Sixteen hours after treatment with 
nocodazole, the cells were harvested, washed with PBS, and probed with the CycleTEST 
Plus DNA reagent kit (Becton-Dickinson). Flow cytometric determination of the DNA 
content was analyzed using the BD Accuri
TM
 C6 Flow Cytometer (Becton-Dickinson).  
 
Zymography 
To detect the secreted MMPs from shSEMA7A and shMock cells, we carried out a 
gelatin zymography assay (Primary Cell, Sapporo, Japan), according to the 
manufacturer’s instructions with minor modifications. The conditioned media were 
mixed with an SDS sample buffer and separated on gelatin gels. After washing, the gels 
were incubated for 32 hours at 37°C in the enzymatic reaction buffer. The gels then were 
stained with Coomassie brilliant blue and destained in a methanol/acetic acid solution 
with gentle agitation on a shaking plate. The MMPs were identified by the presence of 
clear bands in a background with uniform staining. 
 
Cycloheximide (CHX) treatment 
CHX, a common reagent for inhibition of protein synthesis, has been reported to inactive 
the MMPs functions. Since several studies have showed that the Ki of CHX ranges from 
1 to 50 μg/ml [22-27], we used CHX (WAKO, Osaka, Japan) at a concentration of 1 
μg/ml for 48 hours. After treatment, immunoblotting analysis and zymography were 
performed. 
 Transient up-regulation in SEMA7A knockdown cells 
Recent study has been reported that TGF-β1 (R&D Systems, Minneapolis, MN, USA) 
increases the expression level of SEMA7A through a SMAD2/3-independent pathway [28]. 
Since, we have treated shSEMA cells with TGF-β1 at a concentration of 1 ng/mL for 12 hours. 
After treatment, mRNA expression and immunoblotting analyses were performed. 
 
Semiquantitative IHC 
Semiquantitative IHC (sq-IHC) of the 4-µm sections of paraffin-embedded OSCC 
clinical specimens was performed.  Briefly, after paraffinization, hydration, activation of 
antigen, hydrogen peroxide quenching and blocking, the clinical sections were incubated 
with mouse anti-SEMA7A monoclonal antibody (Santa Cruz Biotechnology) at 4°C in a 
moist chamber overnight. Upon incubation with the primary antibody, the specimens 
were washed three times with PBS and treated with Envision reagent (DAKO, 
Carpinteria, CA, USA) followed by color development in 3,3’-diaminobenzidine 
tetrahydrochloride (DAKO). The slides then were counterstained lightly with 
hematoxylin, dehydrated with ethanol, cleaned with xylene, and mounted. To quantify 
the status of the SEMA7A protein expression in clinical samples, we used the sq-IHC 
scoring systems described previously [19, 29-33]. The mean percentages of positive 
tumoral cells were determined in at least three random fields in each section, and the 
intensity of the SEMA7A-immunoreaction was scored as follows: 0+, none; 1+, weak; 
2+, moderate; and 3+, intense. The staining intensity and the cellular numbers were 
multiplied to produce a SEMA7A sq-IHC score. To determine the cutoff points of the 
SEMA7A sq-IHC scores, we analyzed the sq-IHC scores of 150 patients using receiver 
operating characteristic (ROC) curves and the Youden index. Cases with a score over 
69.5 were defined as SEMA7A-positive. Two independent pathologists from Chiba 
University Hospital, neither of whom had knowledge of the patients’ clinical status, 
made these judgments. To calculate the 5-year survival rate, we surveyed each patient’s 
life and month of death. 
 
Statistical analysis 
To compare SEMA7A expression levels, statistical significance was evaluated using the 
Mann-Whitney U test. Relationships between SEMA7A sq-IHC staining scores and 
clinicopathological profiles were evaluated using the χ2 test, Fisher’s exact test, 
Student’s t-test, and Mann-Whitney U test. The 5-year survival rate was evaluated 
using the log-rank test. P<0.05 was considered statistically significant. The data are 
expressed as the mean ± the standard error of the mean (SEM).  
 
Results 
Evaluation of SEMA7A expression in OSCC-derived cell lines 
To investigate the expression status of SEMA7A, we performed qRT-PCR and 
immunoblotting analyses using nine OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, 
Sa3, Ca9-22, SAS, KOSC-2, Ho-1-u-1, and Ho-1-N-1) and HNOKs. SEMA7A mRNA 
was up-regulated significantly (P<0.05) in all OSCC-derived cell lines compared with the 
HNOKs (Fig. 1A). We also performed immunoblotting analysis to investigate the 
SEMA7A protein expression in the OSCC-derived cell lines and the HNOKs (Fig. 1B). A 
significant increase in SEMA7A protein expression was seen in all OSCC-derived cell 
lines compared with the HNOKs.  
 Establishment of SEMA7A knockdown cells 
Since frequent up-regulation of SEMA7A was observed in OSCC-derived cells (Fig. 1), 
we transfected SEMA7A shRNA or shMock in OSCC-derived cells (SAS and KOSC-2). 
To investigate SEMA7A mRNA and protein expressions in shSEMA7A cells, qRT-PCR 
and immunoblotting analyses were performed (Fig. 2A, B, respectively). The SEMA7A 
mRNA expression in shSEMA7A cells was significantly (P<0.05) lower than in shMock 
cells (Fig. 2A). The SEMA7A protein level in the shSEMA7A cells also was decreased 
compared with shMock cells (Fig. 2B). 
 
Functional analyses of SEMA7A knockdown cells 
To investigate the effect of SEMA7A knockdown on cellular proliferation, we 
monitored cellular growth for 168 hours. Cellular growth in shSEMA7A cells decreased 
significantly (P<0.05) compared with the shMock cells (Fig. 3A). We also performed 
cellular invasiveness and migration assays to assess the biologic effects of SEMA7A 
knockdown cells. In an invasiveness assay, the number of penetrating shSEMA7A cells 
significantly (P<0.05) decreased compared with the shMock cells (Fig. 3B). In the 
migration assay, when we visually monitored the area of uniform wounds in confluent 
cell culture, the wounds in the shSEMA7A cells closed significantly (P<0.05) later than 
those in the shMock cells (Fig. 3C). Therefore, shSEMA7A cells showed not only 
decreased cellular proliferation but also decreased invasiveness and migratory abilities.  
 
Cell-cycle analysis of shSEMA7A cells 
Since the cellular growth of the SEMA7A knockdown cells decreased (Fig. 3A), we 
investigated the cell-cycle distributions using flow cytometry. The percentage of the cells 
in the G1 phase in shSEMA7A cells was significantly (P<0.05) higher than that in the 
shMock cells (Fig. 4A).We also assessed the expression levels of the G1 arrest-related 
proteins, such as CDKIs (p21
Cip1 
and p27
Kip1
), cyclins, and CDKs. As expected, the 
CDKIs were up-regulated, and cyclin D1, cyclin E, CDK2, CDK4, and CDK6 were 
down-regulated significantly (P<0.05) in the shSEMA7A cells (Fig. 4B). These results 
indicated that shSEMA7A cells inhibited cellular proliferation by cell-cycle arrest at the 
G1 phase. 
 
Reduced secretion of MMPs and expressin of MT1-MMP in SEMA7A knockdown 
cells 
Since the invasiveness and migratory abilities in SEMA7A knockdown cells decreased (Fig. 
3B, C), we assessed MMPs-mediated matrix proteolysis by qRT-PCR and a MMP 
zymography assay. MMP2 and MMP9 mRNA expressions in the shSEMA7A cells were 
significantly (p<0.05) lower than in the shMock cells (Fig. 5A). In the shSEMA7A cells, 
secretion of MMP2, proMMP-2, and proMMP-9 clearly decreased compared with shMock 
cells. CHX treated shMock cells inhibited the secretion of MMP-2, proMMP-2, and pro-
MMP-9. The levels of secreted MMP were represented as the normalized secretion index, 
which was calculated as the percentage of secreted MMP relative to that of the shMock cells 
(Fig. 5B). We also assessed MT1-MMP by qRT-PCR and immunoblotting analyses (Fig. 6A, 
B, respectively). The MT1-MMP mRNA expression in shSEMA7A cells was significantly 
(P<0.05) lower than in shMock cells (Fig. 6A). The MT1-MMP protein level in the 
shSEMA7A cells also was decreased compared with shMock cells (Fig. 6B). CHX treated 
shMock cells also inihibited the expression of  MT1-MMP expression. These findings 
strongly suggested that SEMA7A was an essential molecule for MMPs’ secretion and 
expression. 
 
Inactivation of the ERK1/2 and AKT pathways in SEMA7A knockdown cells 
We assessed the phosphorylation levels of ERK1/2 and AKT in shSEMA7A by 
immunoblotting analysis. The levels of pERK1/2 and pAKT protein decreased 
significantly (p<0.05) in the shSEMA7A cells compared with shMock cells (Fig. 7A, B). 
These results suggested that the ERK1/2 and AKT signaling pathways were attenuated 
frequently in the shSEMA7A cells. 
 
SEMA7A expression in SEMA7A knockdown cells after TGF-β1 treatment  
To investigate the effect of TGF-β1 on SEMA7A expression, we treated the transfectants 
with TGF-β1. The SEMA7A mRNA in the TGF-β1 treated shSEMA7A cells were 
significantly up-regulated compared with TGF-β1 non-treated shSEMA7A cells (Fig. 8).  
 
Phosphorylation levels of ERK1/2 and AKT in SEMA7A  knockdown cells 
with/without TGF-β1  
We assessed the phosphorylation levels of ERK1/2 and AKT as well as SEMA7A 
expression in SEMA7A knockdown cells with/without TGF-β1 by immunoblot analysis. 
The SEMA7A protein level in the TGF-β1 treated shSEMA7A cells was increased 
compared with the non-treated shSEMA7A cells. In addition, TGF-β1 treated shSEMA7A 
cells showed increased pERK and pAKT levels compared with non-treated shSEMA7A 
cells (Fig. 9).  
 
Evaluation of SEMA7A expression in primary OSCCs 
To investigate the expression status of SEMA7A in primary OSCCs and the relation to 
the clinicopathological characteristics, we analyzed the SEMA7A protein expression in 
primary OSCCs from 150 patients using a sq-IHC scoring system. The SEMA7A protein 
expression of primary OSCCs was significantly (P<0.05) higher than in normal tissues 
(Fig. 10A-C). The SEMA7A sq-IHC scores in OSCCs and adjacent normal oral tissues 
ranged from 36.7 to 203.8 (median, 109.3) and 13.5 to 87.5 (median, 37.9), respectively 
(Fig. 10C). To determine an optimal cutoff point of the identified sq-IHC scores, we used 
ROC curve analysis and the Youden index. The ROC curve analysis area under the curve 
(AUC) was 0.91 (95% confidence interval [CI], 0.8749-0.9378, P<0.05) and Youden 
index (sensitivity, 70.5%; specificity, 96.7%, P<0.05) showed that the cutoff value was 
69.5 (Fig. 10D, E). The correlations between the clinicopathological characteristics of 
the patients with OSCC and the status of the SEMA7A protein expression are shown in 
Table 1. Among the clinical classifications, the SEMA7A-positive OSCCs were 
correlated significantly (P<0.05) with larger tumors, frequent regional lymph node 
metastasis, and advanced clinical stages. The 5-year survival rates in the SEMA7A-
positive OSCCs (n=106) and the SEMA7A-negative OSCCs (n=44) were 76.3% and 
85.3%, respectively. The survival rates in the SEMA7A-positive group were lower than 
in the SEMA7A-negative group, but the difference did not reach significance (P=0.27) 
(S1 Fig.).  
  
Discussion 
The current study found that SEMA7A was overexpressed frequently in all OSCC-
derived cell lines (Fig. 1) and that SEMA7A knockdown cells decreased not only cellular 
proliferation but also invasiveness and migration via cell-cycle arrest at the G1/S phase 
and inhibited secretion and expression of MMPs through the ERK1/2 and AKT pathways 
(Figs. 3-9). Interestingly, SEMA7A-positive OSCCs were correlated significantly with 
tumoral size, regional lymph node metastasis, and clinical stages (Fig. 10, Table 1). 
SEMA7A participates as a tumoral suppressor protein in melanoma progression 
[34]. In contrast, recent studies have reported that SEMA7A was overexpressed in breast 
cancer, melanoma, and glioblastoma and may contribute to tumoral cell migration and 
tissue remodeling in the tumoral microenvironment [2, 35, 36]. Therefore, SEMA7A 
plays pivotal roles in tumoral progression and metastasis of several types of cancers. 
In addition to mediating cellular adhesion, integrins make transmembrane 
connections to the cytoskeleton and activate many intracellular signaling pathways, 
tumoral invasiveness, metastasis, and angiogenesis [37-40]. Since SEMA7A contains an 
integrin-binding motif, RGD28 (amino acids 267–269) [41], inactivation of ERK1/2 and 
AKT in our SEMA7A knockdown cells may result from SEMA7A-β1-integrin ligation. 
ERK1/2 and AKT are central mediator for numerous downstream molecules that regulate 
the Cip/Kip family (p21
Cip1
 and p27
Kip1
) negatively and CDK complexes positively [42, 
43]. The Cip/Kip family is implicated in the negative regulation of the cell-cycle 
progression from the G1 to S phase by modulating CDK activity [44-48]. The activated 
ERK1/2 and AKT pathways also are related to the invasive phenotype of tumoral cells 
via up-regulation of MMPs, which proteolytically degrade various components of the 
extracellular matrix [49]. Of them, MMP-2 and MMP-9 have the unique ability to 
degrade type IV collagen, a major component of the basement membrane. MT1-MMP is 
a membrane-tethered MMP that has been shown to facilitate invasion of tumor cells 
through interstitial collagen by accomplishing proteolysis type I collagen [23, 50]. 
Accordingly, elevated expressions of MMP-2, MMP-9, and MT1-MMP are associated 
with increased metastatic potential in many tumoral cells, and inhibition of MMP 
activities results in reduced tumoral invasiveness and metastasis [51, 52]. In addition to 
our in vitro data from SEMA7A knockdown models in previous reports, the patients with 
SEMA7A-positive OSCC tended to have increased tumoral sizes and lymph node 
metastasis (Table 1). 
In conclusion, we explored the biologic role of SEMA7A in human oral cancer in 
the current study. While further studies are needed to study SEMA7A signaling in the 
cancer microenvironment, we suggested that overexpression of SEMA7A may directly 
affect tumoral growth and metastasis in OSCCs and that SEMA7A is a potential 
biomarker of aggressive tumoral progression and a potential therapeutic target for OSCCs.  
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Legends 
Fig. 1. Evaluation of SEMA7A expression in OSCC-derived cell lines. (A) Quantification 
of SEMA7A mRNA expression in OSCC-derived cell lines by qRT-PCR analysis. Significant 
(✽P<0.05, Student’s t-test) up-regulation of SEMA7A mRNA is seen in seven OSCC-
derived cell lines compared with the HNOKs. Data are expressed as the mean ± SEM of 
triplicate results. (B) Immunoblotting analysis of SEMA7A protein in OSCC-derived cell 
lines and HNOKs. SEMA7A protein expression is up-regulated in OSCC-derived cell 
lines compared with that in the HNOKs. Densitometric SEMA7A protein data are 
normalized to the GAPDH protein levels. The values are expressed as a percentage of the 
HNOKs. 
 
Fig. 2. Establishment of SEMA7A knockdown cells. (A) Expression of SEMA7A mRNA in 
shMock and shSEMA7A cells (SAS and KOSC-2-derived transfectants). SEMA7A mRNA 
expression in shSEMA7A cells is significantly (✽P<0.05, Student’s t-test) lower than in the 
shMock cells. (B) Immunoblotting analysis shows that the SEMA7A protein levels in the 
shSEMA7A cells also are decreased markedly compared with the shMock cells. 
 
Fig. 3. Functional analyses of SEMA7A knockdown cells. (A) Cellular proliferation 
assay of shMock and shSEMA7A cells (SAS and KOSC-2-derived transfectants). To 
determine the effect of shSEMA7A on cellular proliferation, shMock and shSEMA7A cells 
were seeded in 6-cm dishes at a density of 1×10
4
 viable cells/well. The cellular growth of 
shSEMA7A cells is inhibited significantly compared with the shMock cells after 4 days (96 
hours). The results are expressed as the means ± SEM of values from three assays (✽P<0.05, 
Student’s t-test). (B) Invasiveness assay of shMock and shSEMA7A cells (SAS and 
KOSC-2-derived transfectants). To evaluate the effect of SEMA7A knockdown on 
invasiveness, we seeded 2.5×10
5
 cells in the serum-free medium of Matrigel
®
-coated 
Transwell
®
 inserts (8 μm pores) and added serum-supplemented medium in the lower 
chamber as a chemoattractant. After incubation at 37°C for 48 hours, cells that  penetrated 
through the pores were fixed, stained, and counted using a light microscope at ×100 
magnification. The number of shSEMA7A cells penetrating through the pores is decreased 
significantly (✽P<0.05, Student’s t-test) compared with the shMock cells. The mean value 
was calculated from data obtained from three separate chambers.  (C) Migration assay of 
shMock and shSEMA7A cells (SAS and KOSC-2-derived transfectants). To evaluate the 
effect of SEMA7A knockdown on migration, uniform wounds were made in confluent 
cultures of the shSEMA7A and shMock cells and the extent of closure was monitored 
visually every 6 hours for 12 hours. The mean value was calculated from data obtained 
from three separate chambers. The wound area is decreased significantly (✽P<0.05, 
Student’s t-test) in the culture of shMock cells after 12 hours, whereas a gap remained in 
the shSEMA7A cells.  
 
Fig. 4. Cell-cycle analysis of SEMA7A knockdown cells. (A) Flow cytometric analysis was 
performed to investigate cell-cycle progression in the shSEMA7A and shMock cells (SAS 
and KOSC-2-derived transfectants) after synchronization at the G2/M phase to using 
nocodazole. The percentage of cells at the G1 phase in the shSEMA7A cells is increased 
markedly compared with the shMock cells. (B) Immunobloting analysis shows up-regulation 
of p21
Cip1
 and p27
Kip1
 and down-regulation of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 
in the shSEMA7Acells (SAS and KOSC-2-derived transfectants) compared with the shMock 
cells. 
 Fig. 5. Reduced secretion of MMPs in SEMA7A knockdown cells. (A) Expressions of 
MMP-2 and MMP9 mRNA in shMock and shSEMA7A cells (SAS and KOSC-2-derived 
transfectants). MMP-2 and MMP9 mRNA expressions in shSEMA7A cells are significantly 
(✽p<0.05, Student’s t-test) lower than in shMock cells. (B) Secretions of MMP-2, proMMP-
2, and proMMP-9 in shMock and shSEMA7A cells were analyzed by gelatin zymography. In 
the shSEMA7A cells, secretion of MMP2, proMMP-2, and proMMP-9 are clearly decreased 
compared with shMock cells. In addition, CHX treated shMock cells inhibited the secretion 
of MMP-2, proMMP-2, and pro-MMP-9. Densitometric MMP-2, proMMP-2, and proMMP-9 
levels are normalized to shMock levels.  
 
Fig. 6. Reduced expression of MT1-MMP in SEMA7A knockdown cells. (A) Expression 
of MT1-MMP mRNA in shMock and shSEMA7A cells (SAS and KOSC-2-derived 
transfectants). MT1-MMP mRNA expression in shSEMA7A cells are significantly (✽P<0.05, 
Student’s t-test) lower than in shMock cells. (B) Immunoblotting analysis shows that the 
MT1-MMP protein levels in the shSEMA7A cells are also decreased markedly compared 
with the shMock cells. CHX treated shMock cells also inihibited the expression of  MT1-
MMP expression. Densitometric MT1-MMP protein data are normalized to the GAPDH 
protein levels. 
 
Fig. 7. Inactivation of the ERK1/2 and AKT pathways in SEMA7A knockdown cells. (A, 
B) Immunoblotting analysis shows that SEMA7A knockdown results in decreased levels of 
pERK1/2 and pAKT compared with the shMock cells (SAS and KOSC-2-derived 
transfectants). Densitometric pERK1/2, ERK1/2, pAKT, and AKT protein data are 
normalized to GAPDH protein levels. 
 
Fig. 8. SEMA7A expression in SEMA7A knockdown cells after TGF-β1 treatment.  The 
mRNA levels of SEMA7A in TGF-β1 incubated shSEMA7A cells (SAS and KOSC-2) are 
increased significantly (SAS, *P = 0.0022, **P = 0.0021, †P = 0.0001, ††P = 0.0005, 
Student’s t-test) (KOSC-2, *P = 0.0003, **P = 0.0003, †P = 0.0029, ††P = 0.0045, 
Student’s t-test) compared with that in TGF-β1 unincubated shSEMA7A cells. 
 
Fig. 9. Phosphorylation levels of ERK1/2 and AKT in SEMA7A  knockdown cells 
with/without TGF-β1  
Immunoblot analysis of the phosphorylation levels of SEMA7A, ERK1/2, and AKT. 
SEMA7A knockdown results in decreased levels of pERK1/2 and pAKT compared with the 
shMock cells (SAS and KOSC-2-derived transfectants). TGF-β1 treated shSEMA7A cells 
show increased SEMA7A level compared with TGF-β1 non-treated shSEMA7A cells. The 
pERK1/2 and pAKT level also show increased in TGF-β1 treated shSEMA7A cells.  
 
Fig. 10. Evaluation of SEMA7A expression in primary OSCCs.  (A, B) 
Representative sq-IHC results of SEMA7A in primary OSCCs and normal oral 
tissues. Original magnification, ×200. Scale bars, 50 μm.  (C) The status of 
SEMA7A protein expression in primary OSCCs (n=150) and normal 
counterparts based on the sq-IHC scoring system. The SEMA7A sq-IHC scores 
for OSCCs and normal oral tissues range from 36.7 to 203.8 (median, 109.3) and 
13.5 to 87.5 (median, 37.9), respectively. SEMA7A protein expression levels in 
OSCCs are significantly higher than in normal oral tissues (*P<0.05, Student’s 
t-test). (D) ROC curve analysis revealed that the optimal cutoff point is 69.5 
(AUC, 0.91; 95% CI, 0.8749-0.9378; P<0.05). (E) Youden index analysis shows 
that the optimal cutoff point is 69.5 (sensitivity, 70.5%; specificity, 96.7%, 
P<0.05).  
 
Supporting Information 
S1 Fig. Five-year survival rate. The SEMA7A expression level is not correlated 
significantly (P=0.27, log-rank test) with 5-year survival. The 5-year survival rates in the 
SEMA7A-positive OSCCs (n=106) and the SEMA7A-negative OSCCs (n=44) are 76.3% 
and 85.3%, respectively. 
  
Table 1. Correlation between SEMA7A expression and clinical classification in OSCCs.  
Clinical classification 
  Results of immunostaining 
No. of patients 
  
  
  Total SEMA7A- 
negative 
SEMA7A- 
positive 
p value 
Age at surgery (years) 
    
  <60 46 16 30 
0.6420
c
   ≧60, <70 47  7 40 
  ≧70 57 21 36 
     
Gender 
    
  Male 101 29 72 
0.4770
b
 
  Female 49 15 34 
     
T-primary tumor 
    
  T1 28 13 15 
  0.0254
 c*   T2 57 17 40 
  T3 27  6 21 
  T4 38  8 30 
    
N-regional lymph node 
   
  Negative 93 38 55 
  0.0002
 b*
 
  Positive 57  6 51 
     
Stage 
    
  I 26 11 15 
  0.0006
 c*
 
  II 43 18 25 
  III 25  7 18 
  IV 56  8 48 
     
Vascular invasion 
    
Negative 110 35 75 
0.1833
b
 
Positive 40  9 31 
     
Histopathologic type     
  Well 99 28 71 
0.9762
c
   Moderately 42 16 26 
  Poorly 9  0  9 
     
Tumoral site 
    
  Gingiva 39 11 28 
0.5851
a
 
  Tongue 89 29 60 
  Buccal mucosa 8  1  7 
Oral floor 11  3  8 
  Soft palate 3  0  3 
Asterisks indicate significance.  
aχ2 test. bFisher’s exact test. cMann-Whitney U test. 
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